



## Appointment Proposal for an Independent Director

Based on the proposal by the Nominations and Corporate Governance Committee, the Board of Directors of MaaT Pharma proposes to submit the appointment of Mr. Karim Dabbagh as a new independent director for a vote by the shareholders at the Company's next Annual General Meeting to be held on June 19, 2023.

### **Karim Dabbagh, PhD., President and Chief Executive Officer of Second Genome**

Karim Dabbagh, 53 and a French-American dual citizen, was appointed President and CEO of Second Genome in 2018, which he joined as the Chief Scientific Officer in 2014 to build the R&D platform and develop a pipeline of products discovered through the microbial genome mining process.

From 2010 to 2014, he served as Vice President of R&D at Pfizer where he led External R&D Innovation for Immunology, Neurosciences and Cardiovascular/Metabolic Therapy Areas, in addition to his role leading the Immunoregulation department's R&D activities. Before joining Pfizer, Karim was the co-founder of Modus BioMedicine, a biotechnology company focused on treatments for transplantation and autoimmune disease, and he also served as the CEO. Leading to that, Karim spent nine years at Roche in Inflammation Discovery Research. Karim obtained his PhD in Biochemistry from University College, London and his BSc (Hons) in Biotechnology from Imperial College, London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on immune related disorders and mechanisms of immune regulation.



Currently based in the United States, Mr. Karim Dabbagh has an excellent knowledge of the microbiome and brings several decades of high-level experience in pharmaceutical development.